Tuning the tumor, trafficking the T cell: sIRE opens the door for solid tumor CAR T cells
Effective chimeric antigen receptor (CAR) T cell therapy in solid tumors depends on successful tumor engagement, involving trafficking to tumor sites, intratumoral distribution, and sustained cytotoxic function within the tumor microenvironment. In solid tumors, T cells are frequently excluded from the tumor core and at times remain at the periphery or in the stroma, wherein the extracellular matrix restricts T cell migration within the tumor and limits direct interaction of the tumor and immune cells.
Authors
- Govindarajan Srimathveeravalli (ORCID: https://orcid.org/0000-0001-8885-3830)
- Prasad S. Adusumilli (ORCID: https://orcid.org/0000-0002-1699-2046)
- Bilguun Erkhem‐Ochir (ORCID: https://orcid.org/0000-0002-4692-4896)
- Prachi Jalan
- Srijita Banerjee
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- University of Massachusetts Amherst (US)
Publication Details
- Journal
- Molecular Therapy Oncology
- Published
- 2026-06-30
- DOI
- https://doi.org/10.1016/j.omton.2026.201275
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Joanne and John Dallepezze Foundation
- U.S. Department of Defense
- Novocure
- Derfner Foundation
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases